retatrutide phase 2 nejm 2023 obesity trial results For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral semaglutide at a dose of 50 mg Retatrutide: A Triple Agonist Shaping

Are drugs like Mounjaro, Ozempic and Wegovy a better choice than surgery

While it was noted that the level of association between diabetes and pancreatitis fell when adjusted for other factors that could cause pancreatitis, the study concluded that type-2 diabetes may be associated with an increased risk

62% of US beauty and personal care buyers are interested in hyper-personalized products, and 28% are willing to pay extra for them

They will review your information and if appropriate, will create your treatment plan and prescribe weight loss medication

Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies